August 14, 2024
The US Food and Drug Administration (FDA) has approved axatilimab (Niktimvo, Incyte Corporation) for the treatment of adult and pediatric patients with chronic graft versus host […]
August 14, 2024
The US Food and Drug Administration (FDA) granted accelerated approval for Livdelzi (seladelpar, Gilead Sciences, Inc.) for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid […]
August 14, 2024
The European Commission has approved a combination of an immunotherapy agent with a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of certain patients with primary […]
August 13, 2024
On August 13, 2024, the US Food and Drug Administration (FDA) approved nemolizumab for the treatment of adults with prurigo nodularis (PN). A first-in-class monoclonal antibody […]
August 12, 2024
The US Food and Drug Administration (FDA) has approved palopegteriparatide (Yorvipath) for the treatment of hypoparathyroidism in adults, the drug’s manufacturer Ascendis Pharma announced. In hypoparathyroidism, […]
August 9, 2024
The US Food and Drug Administration (FDA) has declined to approve a treatment that combines the psychedelic drug midomafetamine with assisted therapy (MDMA-AT) for the treatment […]
August 9, 2024
Aug. 9, 2024 – An epinephrine nasal spray to treat serious allergic reactions may soon be available in the U.S. The FDA announced its approval of […]
August 9, 2024
The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at […]
August 8, 2024
The US Food and Drug Administration (FDA) has approved the first nalmefene hydrochloride auto-injector (Zurnai; Purdue Pharma LP) for the treatment of known or suspected opioid […]